Chronic Sinus Congestion, Chronic Sinus Infection, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior
Conditions
Brief summary
This study is intended to assess the impact of a 90 day course of high volume budesonide irrigations for patients who have failed other medical therapy and assessing the impact of the budesonide irrigations on the need for sinus surgery.
Detailed description
Patient who meet eligibility requirements will be given the opportunity to use a budesonide saline rinse twice daily for 90 days. At the completion of this therapy, their clinical situation will be reassessed and patients will either proceed to surgery or not. If eligible patients choose not participate, they will be offered surgery up front. The study will be assessing symptom scores using the SNOT-22 validated patient reported symptoms score, CT scans, and other measures. The study hypothesizes that a significant portion of patients that otherwise would have progressed to surgery will no longer need to have surgery based upon improvements in their overall symptoms scores after using budesonise irrigations.
Interventions
DRUGBudesonide
Nasal saline irrigations with budesonide
Sponsors
Kaiser Permanente
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Non randomized, single arm, prospective
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* adult (\>18 yo) * symptoms consistent with sinusitis for at least 12 weeks, * undergone maximal medical therapy, including: extended course of antibiotics (21 days minimum), use of topical corticosteroids for a minimum of 6 weeks, use of saline rinses at least once a day for a minimum of 3 weeks * CT showing evidence of chronic sinusitis.
Exclusion criteria
* pregnant women, * age below 18, * presence of nasal polyps or other nasal masses, * failure to complete medical therapy, * normal CT scan, * intolerance to budesonide or saline irrigations via squeeze bottle (high volume, high flow).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SinoNasal Outcome Test (SNOT 22) | 12 months | Improvement in SNOT 22 scores, using a total score value. The total score can range from 0 to 110 in its composite score, with higher values indicating worse symptoms. The outcome would measure improvements beyond the Minimal Clinically Important Difference (MCID) score of 8.9 lower (lower indicating improvement of symptoms). |
Countries
United States
Outcome results
None listed